Aquestive Therapeutics to Report Fourth Quarter 2024 Financial Results and Recent Business Highlights on March 5 and Host Conference Call on March 6 at 8:00 a.m. ET

Core Viewpoint - Aquestive Therapeutics, Inc. is set to report its fourth quarter results for the period ending December 31, 2024, and will provide updates on recent business developments on March 5, 2025, after market close [1] Company Overview - Aquestive Therapeutics is a pharmaceutical company focused on advancing medicines that significantly improve patients' lives through innovative science and delivery technologies [4] - The company is developing orally administered products to deliver complex molecules, offering alternatives to invasive and inconvenient standard therapies [4] - Currently, Aquestive has five commercialized products marketed in the U.S. and globally, and it is the exclusive manufacturer of these licensed products [4] - The company collaborates with other pharmaceutical companies to bring new molecules to market using proprietary technologies, such as PharmFilm® [4] - Aquestive is advancing a late-stage proprietary product candidate for treating severe allergic reactions, including anaphylaxis, and an earlier stage epinephrine prodrug topical gel for various dermatological conditions, including alopecia areata [4] Upcoming Events - Management will host a conference call for investors on March 6, 2025, at 8:00 a.m. ET, with registration required for participation [2] - A live webcast of the call will be available on the Investors section of the company's website [2] - A replay of the webcast will be accessible for 30 days following the call [3]